

Article

Calcium Binds to Transthyretin with Low Affinity

Cristina Cantarutti ^{1,2} , Maria Chiara Mimmi ³, Guglielmo Verona ⁴, Walter Mandaliti ¹, Graham W. Taylor ⁴, P. Patrizia Mangione ^{3,4}, Sofia Giorgetti ^{2,3}, Vittorio Bellotti ^{2,4,5} and Alessandra Corazza ^{1,2,*} 

¹ Department of Medicine, University of Udine, 33100 Udine, Italy; cristina.cantarutti@uniud.it (C.C.); walter.mandaliti@uniud.it (W.M.)

² Istituto Nazionale Biostrutture e Biosistemi, 00136 Rome, Italy; sofia.giorgetti@unipv.it (S.G.); v.bellotti@ucl.ac.uk (V.B.)

³ Department of Molecular Medicine, Institute of Biochemistry, University of Pavia, 27100 Pavia, Italy; chiara.mimmi@unipv.it (M.C.M.); palma.mangione@unipv.it (P.P.M.)

⁴ Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, University College London, London NW3 2PF, UK; g.verona@ucl.ac.uk (G.V.); graham.taylor@ucl.ac.uk (G.W.T.)

⁵ Scientific Direction, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy

* Correspondence: alessandra.corazza@uniud.it

Abstract: The plasma protein transthyretin (TTR), a transporter for thyroid hormones and retinol in plasma and cerebrospinal fluid, is responsible for the second most common type of systemic (ATTR) amyloidosis either in its wild type form or as a result of destabilizing genetic mutations that increase its aggregation propensity. The association between free calcium ions (Ca^{2+}) and TTR is still debated, although recent work seems to suggest that calcium induces structural destabilization of TTR and promotes its aggregation at non-physiological low pH in vitro. We apply high-resolution NMR spectroscopy to investigate calcium binding to TTR showing the formation of labile interactions, which leave the native structure of TTR substantially unaltered. The effect of calcium binding on TTR-enhanced aggregation is also assessed at physiological pH through the mechano-enzymatic mechanism. Our results indicate that, even if the binding is weak, about 7% of TTR is likely to be Ca^{2+} -bound in vivo and therefore more aggregation prone as we have shown that this interaction is able to increase the protein susceptibility to the proteolytic cleavage that leads to aggregation at physiological pH. These events, even if involving a minority of circulating TTR, may be relevant for ATTR, a pathology that takes several decades to develop.

Keywords: TTR; amyloidosis; mechano-enzymatic mechanism; microcalcification; calcium dysregulation



Citation: Cantarutti, C.; Mimmi, M.C.; Verona, G.; Mandaliti, W.; Taylor, G.W.; Mangione, P.P.; Giorgetti, S.; Bellotti, V.; Corazza, A. Calcium Binds to Transthyretin with Low Affinity. *Biomolecules* **2022**, *12*, 1066. <https://doi.org/10.3390/biom12081066>

Academic Editor: Vladimir N. Uversky

Received: 18 July 2022

Accepted: 29 July 2022

Published: 2 August 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Transthyretin (TTR) is a protein present in plasma and cerebrospinal fluid (CSF), which acts as a transporter of the thyroid hormone thyroxine (T4). It is also involved in the transport of retinol through the interaction with retinol binding protein (RBP). TTR has been recognized as the precursor of systemic amyloidosis both in its wild type form, responsible for wild type TTR amyloidosis (ATTRwt), which affects 10–25% of people over 80 years of age [1], and in its more than 100 variants causing hereditary TTR amyloidosis (ATTRv). A possible protective role of TTR in Alzheimer's disease has also been postulated [2]. In addition, TTR can bind a range of different ligands and can therefore act as a ligand reservoir in the same way as albumin. To date, a broader functional role for TTR cannot be excluded. The mechanism underlying the conversion of soluble globular TTR into insoluble amyloid fibrils has undergone extensive investigation starting from the seminal observation that the full-length protein can form aggregates in acidic conditions [3]. Aggregates formed under these conditions comprise full-length TTR only, although analysis of the biochemical composition of ex vivo TTR amyloid fibrils has highlighted, in most cases, the presence of both full-length and fragmented TTR in the deposits [4].

The investigation of the role of proteolysis in TTR amyloidogenesis has more recently led to the identification of a mechano-enzymatic mechanism, characterized by the synergic actions of proteolysis and shear stress, through which genuine amyloid fibrils, comprising both full-length and fragmented TTR, can be generated in a more physiological environment [5–7]. Both these *in vitro* methods have indicated that tetramer disassembly is a crucial step in TTR amyloidogenesis. Tetramer dissociation can be favored by specific destabilizing mutations but what drives or favors the tetramer disassembly, in particular for wild type TTR, is still not completely clear. It has recently been suggested that calcium, whose homeostasis is often dysregulated in the aged population, might play a role in the destabilization of the structure of TTR [8]. In the body, nearly 99% of total calcium is immobilized in the bones as calcium hydroxyapatite and only about 1% is available in the extracellular fluid where its concentration varies between 2.1 and 2.6 mM [9]. Approximately 40% of extracellular calcium is bound to proteins, predominantly to human serum albumin (HSA), 10% is complexed with bicarbonate, citrate, phosphate and lactate anions [10] and that remaining is unbound (~1.3–1.5 mM). It has been known for over 60 years that the TTR fraction of human serum binds calcium with a similar affinity to albumin [11]. The apparent binding constant for HSA–calcium is about 0.6 mM [12] with four similar low-affinity binding sites. Since the initial observations in 1959, little work has been carried out on TTR–calcium binding. Recently, the X-ray structures of wild type TTR in the presence of 200 mM CaCl₂ (pdb: 4mrb [5] and 4n85 [13]) revealed the presence of one or two Ca²⁺ ions bound/dimer in the crystals. On the contrary, a number of different analytical techniques failed to reveal any specific interaction between calcium and TTR in solution [8,13]. The work carried out by Wiczorek and collaborators [8] using a variety of analytical techniques suggests that calcium in the millimolar range destabilizes TTR structure by altering its conformational flexibility towards non-native conformers. Whether calcium actually binds to TTR in solution still remains unclear.

Here, we have applied high-resolution NMR spectroscopy to investigate calcium binding to TTR and we have assessed its effect on TTR aggregation at physiological pH in the presence of both proteolysis and mechanical forces.

2. Materials and Methods

2.1. Protein Expression and Purification

Transformed BL21 star (DE3) cells (Thermo Fisher Scientific, Waltham, MA, USA), containing the peTM11 plasmid encoding hexahistidine-tagged wild type TTR, were plated onto Luria broth (LB)–agar media containing 30 µg/mL kanamycin for overnight incubation at 37 °C. A single colony was isolated and cultured overnight at 37 °C in 5 mL LB medium containing 30 µg/mL kanamycin under shaking conditions (LB/kan). This preparation was inoculated into 1 L LB/kan for an initial growth at 37 °C. When the culture reached OD₆₀₀ = 0.5, the temperature was reduced to 30 °C. Protein expression was induced at OD₆₀₀ = 0.6 by adding IPTG (1 mM final concentration) for overnight incubation. The cells were harvested by centrifugation at 3500 × *g*, suspended in lysis buffer containing 20 mM Tris-HCl pH 8, 250 mM NaCl, 3 mM imidazole and finally sonicated at 4 °C. The supernatant was clarified following 30 min centrifugation at 18,000 × *g* and loaded onto a HisTrap FF crude nickel affinity chromatography column (GE Healthcare, Chicago, IL, USA) equilibrated in lysis buffer. After extensive washing with 20 mM Tris-HCl, 10 mM imidazole, containing stepwise increasing concentrations of NaCl (250 mM, 500 mM and 1 M, respectively), the protein was eluted with 20 mM Tris-HCl, 250 mM NaCl, 250 mM imidazole, pH 8.0. His-tagged TEV protease (Sigma-Aldrich, St. Louis, MO, USA) was added at 1% *w/w* during dialysis to selectively cleave the hexaHistidine-tag, which was then removed by affinity chromatography, together with the enzyme. Fractions containing TTR were pooled and subjected to size exclusion chromatography using a Superdex 75 Hi Load 26/60 column (GE Healthcare, Chicago, IL, USA) equilibrated and eluted with

25 mM Tris-HCl, 100 mM NaCl, pH 8.0. Fractions containing TTR were dialyzed against water at 4 °C for at least 3 days and then lyophilized. Purity and molecular weight were determined by SDS-PAGE analysis and mass spectrometry, respectively. For the expression of recombinant [75% ^2H , ^{13}C , ^{15}N] wild type TTR, the initial overnight culture was adapted to grow in a deuterated background by stepwise addition of Ross medium prepared in $^2\text{H}_2\text{O}$ supplemented with ^{15}N ammonium sulfate and with ^{13}C glucose for 7 steps and further growth steps were carried out in the same medium.

2.2. NMR Spectroscopy

NMR spectra were obtained at 700 MHz with a Bruker AVANCE NEO (Bruker, Billerica, MA, USA) on 80–125 μM U-[^2H , ^{13}C , ^{15}N] recombinant TTR samples in 10 mM HEPES buffer at pH 6.5 or 7.4 with and without 154 mM NaCl, in a mixture of $\text{H}_2\text{O}/\text{D}_2\text{O}$ 95/5 *v/v*. A reference 2D [^{15}N , ^1H] TROSY spectrum [14] for apo-TTR was acquired at 25 °C, together with additional spectra at 28, 31, 34, 37 °C, respectively. The spectra at various temperatures were necessary to obtain the assignment at 25 °C from the already known assignment at 37 °C. The 2D [^{15}N , ^1H] TROSY spectra were acquired upon addition of small aliquots of stock CaCl_2 solutions 0.025–2 M with a maximum volume variation of 1.5%.

The 3D HNCA spectra were acquired at 298 K to check the assignment at the final CaCl_2 concentration.

The chemical shift deviation of individual amide pairs, $\Delta\delta$, was defined as [15]:

$$\Delta\delta = \sqrt{(\Delta\delta_{HN})^2 + \left(\frac{\Delta\delta_N}{6.5}\right)^2}.$$

Spectra were processed with Topspin 4.0.9 (Bruker Biospin, Billerica, MA, USA) and analyzed in NMRFAM-SPARKY [16]. The non-linear regression to obtain the dissociation constants was performed with Mathematica 11.

2.3. Electrostatic Calculation

The electrostatic profile of TTR was determined starting from the X-ray structure refined at 1.7 Å resolution (pdb: 1tta [17]) for the core region 10–124, that also contains the N-ter G1-K9 and C-ter P125-E127 regions modeled by simulated annealing. The presence of the two charged terminals of K9, K126 and E127, is essential for a correct evaluation of the overall electrostatic potential. APBS software [18] was used to calculate the electrostatic potential after the necessary addition of hydrogens with VMD tools [19] and after the correct protonation state of histidine residues at neutral pH. We found that H31, H56 and H88 are fully protonated and H90 is protonated in the ϵ position. The electrostatic potential was visualized on the protein surface with Pymol.

2.4. Molecular Dynamics (MD) Simulations

We used as the starting configuration the X-ray structure taken from the RCSB Protein Data Bank (pdb) [20] with id 5cn3, solved at 1.30 Å [21]. The first 9 N-terminal residues and the last 2 C-terminal residues are not present in the structure and we did not model them. The integrity of the crystal structure was checked with Molprobity online software [22] and no missing backbone or side chain atoms were found. With the pdb_delhetatm tool [23], we removed crystallization water molecules and with the pdb2pqr tool [24] we determined the protonation state of histidine residues at pH 7.4. These protonation states were assigned to the structure with VMD [19].

Nanoscale Molecular Dynamics (NAMD) [25] software was used to perform the simulations employing Chemistry at Harvard Macromolecular Mechanics (CHARMM) all atoms force field [26]. We first minimized the prepared structure in vacuum for 500 steps. Then, we placed the minimized structure in the center of a cubic box of $10 \times 10 \times 10 \text{ \AA}^3$ and the system was solvated with a 3-site rigid water model (TIP3P) [27] and neutralized

with 0.1 M NaCl. The resulting protein concentration was approximately 3 mM. CaCl₂ was added in order to obtain the same protein/Ca²⁺ ratio reached at the end of the NMR titration carried out at pH 7.4 in the presence of NaCl. We minimized and equilibrated water to the target temperature of 298 K, keeping the protein and the ions fixed. The minimization was performed for 500 steps and the equilibration run for 20 ps. Then, the same two steps were carried out for the whole system without constraints with an equilibration step of 120 ps. The final production run was performed under NPT conditions for 15 ns, saving coordinates after every ps for analysis. Calcium atoms within 3.5 Å of the protein were identified as interacting ions [28]. The distances between the protein residues and Ca²⁺ were measured over all the trajectory frames to infer the interaction persistency during simulation time.

2.5. Aggregation

Proteolysis-mediated fibrillogenesis of wild type TTR was carried out in glass vials (air/water interface of 1.5 cm²) stirred at 1500 rpm (IKA magnetic stirrer) and at 37 °C for 96 h using 1 mg/mL TTR (corresponding to 18 µM tetrameric TTR) in 10 mM HEPES, 154 mM NaCl, pH 7.4 in the presence of 0 mM, 1 mM, 10 mM, 40 mM and 60 mM CaCl₂, respectively. Proteolysis was initiated by addition of trypsin (5 ng/µL) to yield a final protease to TTR ratio of 1:200 *w/w*. Alteration of trypsin activity due to high CaCl₂ concentration was excluded by testing D-VLK 4-nitroanilide HCl peptide hydrolysis at 310 K using a spectrophotometric assay at 405 nm with and without 60 mM CaCl₂. A control sample subjected to agitation only without enzyme was also included. At the end of the incubation period, aggregation was monitored by light scattering at 400 nm using a Jasco V650 spectrophotometer. Each sample was then centrifuged for 20 min at 10,300× *g*, supernatant was removed and the pellet was washed twice in PBS before being suspended in 100 µL of 10 µM thioflavin T (ThT) in PBS, pH 7.4 for further investigation by ThT emission fluorescence at 480 nm, following excitation at 445 nm, using a FLUOstar Omega plate reader (BMG Labtech, Ortenberg, Germany). A 10 µL aliquot of pellet was stained with alcoholic alkaline Congo red (CR) solution and the pathognomonic amyloid birefringence was observed with polarized light microscopy. Samples were also analyzed by SDS–gradient 4–15% PAGE (BioRad, Hercules, CA, USA) under reducing conditions in order to collect information on protein consumption and formation of amyloidogenic fragments. Statistical analysis on both turbidity and ThT aggregation data was performed using the Friedman test (non-parametric analogue to one-way ANOVA for repeated measures).

3. Results

3.1. Electrostatics of TTR

Since our study concerns the interaction between two charged species, i.e., Ca²⁺ and TTR, we preliminarily assessed the electrostatic properties of TTR. Based on electrostatic calculations, TTR is negatively charged at neutral pH with a pI = 5.35 and a net charge of −8.27 (Figure S1). The electrostatic potential represented on the Connolly surface evidences a moderately positive surface in the frontal view parallel to the channel connecting the thyroxine, T4, binding pockets (Figure 1A), a more positive patch at the entrance of the binding site where the negatively charged T4 enters (Figure 1B) and a large negative region at the apical ends (Figure 1C). Furthermore, a closer look reveals a strongly negatively charged cavity formed by E61, E62, E63, E66 and D99 (Figure 1D) characterized by a prominent negative isopotential surface at −1.0 kT/e with a corresponding positive isopotential surface at 1.0 kT/e much closer to the protein surface (Figure 1E).




Figure 1. Electrostatic potential mapped on the surface of TTR (pdb: 1tta). In (A–C), the whole tetrameric structure with different orientations is depicted, while in (D) the highly negatively charged cavity formed by E61, E62, E63, E66 and D99 is zoomed into and the corresponding ± 1 kT/e isopotential electrostatic field is represented in (E). The dashed circle in panel (A) corresponds to the zoomed in region of panels (D,E). All the calculations were performed using APBS [18] in Pymol.

3.2. Does TTR Bind Ca^{2+} ?

The 2D [^{15}N , 1H] NMR correlation maps provide a very informative fingerprint of a protein, including atomic-level information about the NHs of all residues of a polypeptide chain, except prolines. The chemical shift of each cross-peak is extremely sensitive to the chemical environment and to residue conformation, making the chemical shift perturbation (CSP) analysis a very powerful tool for studying protein–ligand interactions. The changes in peak chemical shift ($\Delta\delta$) are also diagnostic of the rate of the exchange processes, which are classified in NMR based on the deviation of a peak from its reference position. Interacting proteins and ligands are in fast exchange when $k_{ex} = k_{on} + k_{off} \gg \Delta\delta$ and the shift of an exchanging peak is the population-weighted average between the bound and free forms. When $\Delta\delta \gg k_{ex}$, slow exchange occurs and the intensity of the free peak gradually decreases, while the intensity of the bound peak correspondingly increases, linearly with the concentration of the free and bound proteins. In our study, we use the unique capabilities of NMR to investigate, at the residue level, the interaction of TTR with $CaCl_2$ in solution.

TTR is a 55 kDa protein characterized by a correlation time of about 20 ns at 25 °C, estimated from its molecular weight [29]. Such a relatively slow global rotational motion requires the use of specific strategies to overcome the fast signal decay: (1) perdeuteration [30] and (2) use of TROSY sequences [14]. The 2D [^{15}N , 1H] TROSY spectrum of triple labeled [$75\% ^2H$, ^{13}C , ^{15}N] apo-TTR acquired at 16.44 T was previously assigned at 37 °C [31] and




Figure 3. Bar plot of combined NH chemical shift variation recorded at TTR/ Ca^{2+} = 0.2 at pH 6.5 (A), at pH 7.4 (C) and at pH 7.4 in the presence of 154 mM NaCl (E). Gray bars indicate prolines and residues that could not be followed during titration. The red lines correspond to the average value and the black ones to the average + 2σ . Chemical shift perturbation ($\Delta\delta$) observed at pH 6.5 (B), at pH 7.4 (D) and at pH 7.4 with 154 mM NaCl (F) in the presence of CaCl_2 shown in the structure of TTR (pdb: 5cn3) with the same color gradient as in the bar plots.

Site-2, on the other hand, is not clearly detected as neither C10 nor H56 were observed in 2D TROSY at neutral pH, but a clue comes from R104 and K126, which have a $\Delta\delta \gtrsim$ average + 2σ and are spatially close to site-2. The observation of C10 amide at neutral pH is prevented by the exchange with water, but the peak becomes visible when the pH is lowered. We therefore repeated the titration with CaCl_2 at pH 6.5, and indeed C10 is observed and shifts significantly with the addition of Ca^{2+} (Figure 3A). As before, we could not detect H56 NH under our experimental conditions. The CSP of R104 can be explained

by the formation of a hydrogen bond (Hb) that occurs between C10-O and R104-N ϵ upon Ca²⁺ binding (Figure 4C) and is absent without Ca²⁺ (Figure S3A). In addition, the R104 side chain adopts different orientations in the presence and in the absence of Ca²⁺, which affect the opposite amide nitrogen of K126 that actually shifts during titration (Figure S3B).




Figure 4. Ca²⁺ binding sites shown by 4mrB (A) and 4n85 (D) X-ray structures. Chemical shift variation ($\Delta\delta$) as a function of Ca²⁺ concentration for the peaks belonging to binding site-1 at pH 6.5 (B) and at pH 7.4 with 154 mM NaCl (C) and for binding site-2 at pH 6.5 (E) and at pH 7.4 with 154 mM NaCl (F). The lines correspond to the data fitting by Equation (1).

To determine the dissociation constants of the binding of Ca²⁺ to site-1 and -2, CSP data were analyzed using the $TTR + Ca^{2+} \rightleftharpoons TTR - Ca$ model. The observed chemical shift, δ_{obs} , can be expressed as $\delta_{obs} = \delta_{free}\chi_{free} + \delta_{bound}\chi_{bound}$ [32], where δ and χ are the chemical shift and molar fraction of the free and bound forms, as indicated by the subscript. The dissociation constant, K_d , can thus be obtained by a non-linear interpolation of Equation (1):

$$\Delta\delta_{obs} = \Delta\delta_{max} \left\{ \frac{[TTR]_0 + [Ca^{2+}]_0 + K_d - \sqrt{([TTR]_0 + [Ca^{2+}]_0 + K_d)^2 - 4[TTR]_0[Ca^{2+}]_0}}{2[TTR]_0} \right\} \quad (1)$$

where $[TTR]_0$ and $[Ca^{2+}]_0$ are the total concentrations of monomeric TTR and Ca²⁺, respectively, and $\Delta\delta_{max}$ is the maximum chemical shift at saturation. The $\Delta\delta_{obs}$ of NHs belonging to the same binding site were fitted as a system of equations. At pH 6.5, the fitting of CSP data gives for binding site-1 $K_d = (8.7 \pm 2.1)$ mM and for binding site-2 $K_d = (13.5 \pm 1.3)$ mM (Figure 4B,C).

To verify the binding of Ca²⁺ to TTR at physiological pH and salt concentration, 2D TROSY at different Ca²⁺/TTR ratios were also acquired at pH 7.4 and in the presence of 154 mM NaCl. The results show that binding still occurs but the CSP is less pronounced than the one measured without NaCl (Figure 3A,C,E). At high salt concentration, the binding is affected by electrostatic shielding and under these conditions we

obtained $K_d = (32.7 \pm 4.3)$ mM for site-1 (Figure 4C). For site-2, we could not observe any peak corresponding to directly bound residues (H56 and C10), but we estimated the K_d by fitting the chemical shift variation of R104 that is indirectly involved in the interaction with the cation. By fitting R104 CSP (Figure 4F), we obtained $K_d = (40.8 \pm 6.9)$ mM.

From CSP data, other residues that shift by more than the average $+ 2\sigma$ are the negatively charged E51 in loop CD (site-3) and E62 in the loop DE (site-4), which are exposed to the solvent and do not participate in any H bonding. Moreover, E62 is also part of the negatively charged cavity described in Section 3.1. According to CSP analysis, two additional putative binding sites comprise K76 (helix H1) and E89 (loop H1-F) (site-5 in Figure S3C), which are connected by two Hbs, and V14-K15-A25-G53-E54-L55-A109, which are involved in a complex Hb network (site-6 in Figure S3D). The K_d values (Table 1) for these putative binding sites, which were not observed in the X-ray data, were also determined (Figure S3E–H) and are in a similar range as the one measured for site-2.

Table 1. CSP fitting parameters obtained using Equation (1) for the binding sites inferred from NMR data.

Site	K_d (mM)	R^2 ; p -Value
Site-1	8.7 ± 2.1	0.993; 6.3×10^{-3}
Site-2	13.5 ± 1.3	0.999; 5.0×10^{-5}
Site-3	16.1 ± 2.2	0.998; 3.3×10^{-4}
Site-4	16.2 ± 3.8	0.993; 5.4×10^{-3}
Site-5	19.5 ± 6.2	0.973; 6.9×10^{-3}
Site-6	15.4 ± 2.1	0.979; 2.4×10^{-9}

3.3. Binding Specificity

Chemical shift differences in different solvents are usually described by four terms: bulk susceptibility of the solvent, electrostatic screening, van der Waals forces between the protein and the solvent and, finally, hydrogen bond formation [33]. In the case of NaCl, the effect has been mainly described as a consequence of a long-range bulk susceptibility where polarized water produces a small magnetic field with a screening effect on all nuclei with an average chemical shift variation on H^N ($\Delta\delta^H$) of -0.01 ± 0.01 ppm per 100 mM NaCl [33] as probed in hen egg white lysozyme (HEWL). To rule out the possibility that the effect we observed with $CaCl_2$ was due to a generic salt effect, we acquired TTR spectra at different NaCl concentrations. Our results report an average $\Delta\delta^H = -0.006 \pm 0.025$ ppm at 100 mM NaCl (Figure S4) with a clear indication of a less uniform variation in chemical shift than that reported in the literature [33] (for comparison, at 100 mM $CaCl_2$ the average $\Delta\delta^H = -0.022 \pm 0.036$ ppm). It is worth noting that at physiological pH, TTR is a negatively charged protein while HEWL is positively charged ($pI = 9.39$), and that the leading effect of Cl^- , according to the Hofmeister series, may therefore be more pronounced for positively charged proteins. Furthermore, NaCl maps the electrostatic negative regions of TTR similarly to $CaCl_2$ indicating that with both salts a solvent bulk effect can be ruled out. The comparison between $CaCl_2$ and NaCl data highlights that among the six putative binding sites identified, only binding site-1 is specific for Ca^{2+} while the others may indicate sites of localized persistent electrostatic interactions.

3.4. Molecular Dynamics Simulations

MD simulations run for 15 ns in the presence of $CaCl_2$ evidenced that Ca^{2+} clusters in specific regions. To infer the persistency of the interaction, the distances between interacting residues and calcium ions were measured and the percentage of configurations showing distances ≤ 3.5 Å over all the trajectory is plotted in Figure S5A,B. We thus identified that D38, D39, E42, E51, E54, E61, E62, E63, E66, E72, E89, E92 and D99 interact with Ca^{2+} for more than 50% of the simulation time. These residues can be grouped in three negative patches: the apical region including D38, D39, E42, E72, and E92; the cavity made by E61, E62, E63, E66 and D99; and the protruding region that comprises E51 and E54 (Figure S5C).

It is worth noting that D99 is the only residue that during the simulation interacts with calcium not only with its side chain carboxyl, but also with its backbone carbonyl.

3.5. Ca^{2+} Favors TTR Aggregation under Physiological pH

TTR was dissolved in HEPES, pH 7.4 and incubated for 96 h in the presence of different concentrations of CaCl_2 under mechano-enzymatic conditions of fibrillogenesis [5,6]. Aggregation was monitored by both generic light scattering at 400 nm and amyloid-specific ThT emission fluorescence at 480 nm (Figure 5A,B). Good agreement was observed between the two data sets with calcium binding favoring TTR fibrillogenesis at higher concentrations (40 mM and 60 mM), while no significant effect was observed at lower Ca^{2+} concentrations (1 mM and 10 mM) with respect to the Ca^{2+} -free control sample. The median equality of absorbance at 400 nm/ThT emission fluorescence at different levels of CaCl_2 concentration was verified using the Friedman test. The two parameters were measured in the same samples before and after subsequent addition of CaCl_2 to obtain $[\text{Ca}^{2+}] = 0, 1, 10, 40, 60$ mM. The p -value associated with turbidity at 400 nm (0.03875) was smaller than the fixed threshold, $\alpha = 0.05$, while the p -value associated with ThT was not (0.4337). In spite of the intrinsic high data dispersion and the small sample size, these data indicate that fibrillogenesis is favored by high Ca^{2+} concentration. Previous work by our group [6] has shown that in vitro wild type TTR can generate genuine amyloid fibrils, comprising a mixture of both full-length TTR and the amyloidogenic 49–127 C-terminal fragment. The investigation of the aggregated material by SDS-PAGE highlighted an increased formation of aggregation-prone 49–127 TTR fragments in the presence of higher Ca^{2+} concentrations (Figure 5C), which explains the increased rate of aggregation observed. The pathognomonic birefringence under cross-polarized light following Congo red staining was used to confirm the presence of amyloid fibrils in all samples subjected to trypsin digestion.




Figure 5. Effect of calcium on mechano-enzymatic wild type TTR fibrillogenesis. (A) Light scattering signal at 400 nm monitored in the whole sample after 96 h of aggregation. (B) ThT emission fluorescence at 480 nm following excitation at 445 nm measured in pellets after 96 h of aggregation.

Statistical analysis on both turbidity and ThT aggregation data was performed using the Friedman test. (C) SDS 15% PAGE under reducing conditions. Lane a: marker proteins (14.4, 20.1, 30.0, 45.0, 66.0 and 97.0 kDa); lane b: WT TTR; lane c: WT TTR 1 mM Ca^{2+} ; lane d: WT TTR 10 mM Ca^{2+} ; lane e: WT TTR 40 mM Ca^{2+} ; lane f: WT TTR 60 mM Ca^{2+} . 1–127 and 49–127 indicate full-length TTR and the amyloidogenic C-terminal fragment, respectively.

4. Discussion

A number of metal cations, such as Zn^{2+} , Mn^{2+} , $\text{Cu}^{1+,2+}$ and $\text{Fe}^{2+,3+}$, show the formation of a complex with TTR when soaked in crystallization media with high metal concentrations. Zn^{2+} and Cu^{2+} also promote amyloid formation, especially in the L55P variant TTR in the presence of Zn^{2+} [34]. In addition, the protective role of TTR in $\text{A}\beta$ fibril formation and the presence of metal ions in $\text{A}\beta$ amyloid deposits have contributed to increasing the interest in studying the interaction between TTR and metal ions [35–38]. Crystallographic structures show that Ca^{2+} is located at two binding sites, the first formed by E66 and D99 and the second by H56 and C10, located respectively in loop DE, loop FG, loop DE and N-terminus of strand A, without involving the T4 binding pockets. Recently, Wieczorek and colleagues published a very detailed analysis of TTR structural stability in the presence of Ca^{2+} without providing evidence of binding in solution, but showing several effects that can be associated with changes in the hydration shell that could indirectly affect TTR dynamics. An increase in aggregation propensity under non-physiological acidic conditions was also reported [8]. In this study, we show that Ca^{2+} binds with low affinity to TTR in solution without affecting its native structure and that the binding is ionic strength dependent. Indeed, the chemical shift variations of the amides in the 2D TROSY spectra indicate that the TTR structure remains essentially unchanged upon binding. Ca^{2+} also binds to site-1, comprising D99 and E66, in solution with an affinity in the mM range while the other sites may represent local electrostatic interactions as high NaCl concentrations also induce similar spectra variations. The localized effect of NaCl and CaCl_2 mainly in negatively charged TTR regions rules out a generic effect of salts on water in line with other authors that propose a direct interaction between ions and macromolecules in spite of the creation/breaking of bulk water structures [39]. More interestingly, the experiments with NaCl point out that only site-1 is specific for Ca^{2+} while the other sites likely report only of electrostatic interactions without a specific binding site. NMR and electrostatic data together with MD simulations suggest that Ca^{2+} clusters in close proximity to negatively charged patches and only after exploring the protein surface does the cation bind to site-1 with a mM affinity. These data agree with previous MD simulation studies reporting that calcium, before reaching its binding site on calbindin, is detained within 3.5 Å of the protein surface for a long time (approximately 650 ns) during which the cation scans the surface searching for higher affinity binding sites. This specific mechanism appears to be particularly important at low Ca^{2+} concentrations [28]. If electrostatics play a crucial role in Ca^{2+} binding, we should keep in mind that the screening effect of NaCl, which causes the 4-fold increase in K_d measured in vitro with 154 mM NaCl, may be reduced in vivo. In the extracellular matrix, where aggregation takes place, the presence of glycosaminoglycans (GAGs) buffers Na^+ , which in the interstitial fluid bridges GAGs and modulates their polymerization grade, thus reducing free Na^+ concentration [40]. Ca^{2+} affinity close to the protein surface can be modulated in vivo by different players, as aforementioned, but the investigation of these details is outside the aim of our study.

Despite small structural variations, TTR aggregation propensity at physiological pH is favored by Ca^{2+} addition, similarly to the previously reported observations obtained under acidic conditions [8]. Moreover, high Ca^{2+} concentrations favor the proteolytic cleavage with formation of the aggregation-prone 49–127 TTR fragment. Normal extracellular calcium concentration averages at 2.4 mM [9] and can be further locally modulated in terms of distances from interfaces [41]. Considering an extracellular concentration of calcium around 2.4 mM and the K_d values obtained by NMR titration experiments, we can estimate that the percentage of Ca^{2+} -bound TTR in vivo is about 7%. Albeit modest,

these values indicate that a non-negligible percentage of TTR is bound to Ca^{2+} in vivo, thus increasing the susceptibility of a fraction of circulating TTR to serine protease cleavage. In addition, there is recent evidence that microcalcification is a common feature in cardiac tissue of patients affected by cardiac TTR amyloidosis [42], thus suggesting that local calcium concentration in the extracellular space of the heart, where amyloid deposition takes place, may indeed vary. The microcalcifications have a calcium content per gram of tissue about 40,000 times higher than in microcalcification-free areas [43], making the hypothesis of local high calcium content reasonable. Amyloid fibrils containing a mixture of both full-length and fragmented TTR have also been identified in other tissues, such as the vitreous body [4], although whether calcium might be involved in promoting aggregation is difficult to postulate as not enough information about its local concentration is available for these patients. Our findings still leave important questions with clinical relevance open: in addition to a pre-formed TTR– Ca^{2+} complex more prone to fibril formation, is Ca^{2+} able to stabilize aggregation prone partially folded species and/or does an already formed fibril tend to bind calcium and, by doing so, increase the propensity for fibril elongation? An answer to these questions could also be relevant for scintigraphy that is used as a crucial diagnostic tool in the clinic, in which the association of $^{99\text{m}}\text{Tc}$ -3,3-diphosphono-1,2-propanodicarboxylic acid ($^{99\text{m}}\text{Tc}$ -DPD) with amyloid plaques is described as calcium dependent, and in which the presence of microcalcifications in cardiac ATTR appears to be related to DPD specificity for this type of amyloidosis [44].

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/biom12081066/s1>, Figure S1: TTR charge as a function of pH. Figure S2: Overlay of 2D [^1H , ^{15}N] TROSY spectra of TTR titration with calcium at pH 7.4 without and with 154 mM NaCl. Figure S3: RX structures and CSP data fitting of residues involved in putative sites 3–6. Figure S4: Bar plot of TTR H^{N} chemical shift variation with 150 mM NaCl. Figure S5: Results of 15 ns MD simulations.

Author Contributions: Conceptualization, V.B. and A.C.; methodology, C.C., M.C.M. and G.V.; formal analysis, C.C. and A.C.; investigation, C.C., M.C.M., G.V., W.M., G.W.T., P.P.M., S.G., V.B. and A.C.; data curation, C.C.; writing—original draft preparation, A.C.; writing—review and editing, C.C., G.V., G.W.T., V.B. and A.C.; visualization, C.C., M.C.M., G.V. and A.C.; supervision, V.B. and A.C.; project administration, V.B. and A.C.; funding acquisition, V.B. and A.C. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the United Kingdom Medical Research Council Grant MR/R016984/1 (to V.B.), the Italian Ministry of Research and University Dipartimenti di Eccellenza 2018–2022 grant to the Molecular Medicine Department (University of Pavia) and the Istituto Nazionale di Biostrutture e Biosistemi. Core support for the Wolfson Drug Discovery Unit is provided by the United Kingdom National Institute for Health Research Biomedical Research Centre and Unit Funding Scheme via the UCLH/UCL Biomedical Research Centre and by the UCL Amyloidosis Research Fund.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank the Centro Grandi Strumenti of the University of Pavia, Italy, for providing access to the NMR facility and Teresa Recca for technical assistance. We thank Mark B. Pepys FRS FMedSci for inspiring discussions and continuous support.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Westermark, P.; Sletten, K.; Johansson, B.; Cornwell, G.G. Fibril in Senile Systemic Amyloidosis Is Derived from Normal Transthyretin. *Proc. Natl. Acad. Sci. USA* **1990**, *87*, 2843–2845. [[CrossRef](#)] [[PubMed](#)]
2. Schwarzman, A.L.; Gregori, L.; Vitek, M.P.; Lyubski, S.; Strittmatter, W.J.; Enghilde, J.J.; Bhasin, R.; Silverman, J.; Weisgraber, K.H.; Coyle, P.K. Transthyretin Sequesters Amyloid Beta Protein and Prevents Amyloid Formation. *Proc. Natl. Acad. Sci. USA* **1994**, *91*, 8368–8372. [[CrossRef](#)]
3. Colon, W.; Kelly, J.W. Partial Denaturation of Transthyretin Is Sufficient for Amyloid Fibril Formation in Vitro. *Biochemistry* **1992**, *31*, 8654–8660. [[CrossRef](#)]
4. Thylen, C.; Wahlqvist, J.; Haettner, E.; Sandgren, O.; Holmgren, G.; Lundgren, E. Modifications of Transthyretin in Amyloid Fibrils: Analysis of Amyloid from Homozygous and Heterozygous Individuals with the Met30 Mutation. *EMBO J.* **1993**, *12*, 743–748. [[CrossRef](#)]
5. Mangione, P.P.; Porcari, R.; Gillmore, J.D.; Pucci, P.; Monti, M.; Porcari, M.; Giorgetti, S.; Marchese, L.; Raimondi, S.; Serpell, L.C.; et al. Proteolytic Cleavage of Ser52Pro Variant Transthyretin Triggers Its Amyloid Fibrillogenesis. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 1539–1544. [[CrossRef](#)]
6. Marcoux, J.; Mangione, P.P.; Porcari, R.; Degiacomi, M.T.; Verona, G.; Taylor, G.W.; Giorgetti, S.; Raimondi, S.; Sanglier-Cianfèrari, S.; Benesch, J.L.; et al. A Novel Mechano-Enzymatic Cleavage Mechanism Underlies Transthyretin Amyloidogenesis. *EMBO Mol. Med.* **2015**, *7*, 1337–1349. [[CrossRef](#)]
7. Mangione, P.P.; Verona, G.; Corazza, A.; Marcoux, J.; Canetti, D.; Giorgetti, S.; Raimondi, S.; Stoppini, M.; Esposito, M.; Relini, A.; et al. Plasminogen Activation Triggers Transthyretin Amyloidogenesis in Vitro. *J. Biol. Chem.* **2018**, *293*, 14192–14199. [[CrossRef](#)]
8. Wieczorek, E.; Kędracka-Krok, S.; Bystranowska, D.; Ptak, M.; Wiak, K.; Wygralak, Z.; Jankowska, U.; Ozyhar, A. Destabilisation of the Structure of Transthyretin Is Driven by Ca²⁺. *Int. J. Biol. Macromol.* **2021**, *166*, 409–423. [[CrossRef](#)]
9. Carafoli, E.; Krebs, J. Why Calcium? How Calcium Became the Best Communicator. *J. Biol. Chem.* **2016**, *291*, 20849–20857. [[CrossRef](#)]
10. Bushinsky, D.A.; Monk, R.D. Calcium. *Lancet* **1998**, *352*, 306–311. [[CrossRef](#)]
11. Johnson, P.C.; Smith, W.O.; Wulff, B. Calcium-45 Binding by Human Prealbumin. *J. Appl. Physiol.* **1959**, *14*, 859–860. [[CrossRef](#)] [[PubMed](#)]
12. Kragh-Hansen, U.; Vorum, H. Quantitative Analyses of the Interaction between Calcium Ions and Human Serum Albumin. *Clin. Chem.* **1993**, *39*, 202–208. [[CrossRef](#)]
13. Yokoyama, T.; Kosaka, Y.; Mizuguchi, M. Crystal Structures of Human Transthyretin Complexed with Glabridin. *J. Med. Chem.* **2014**, *57*, 1090–1096. [[CrossRef](#)] [[PubMed](#)]
14. Pervushin, K.; Riek, R.; Wider, G.; Wüthrich, K. Attenuated T2 Relaxation by Mutual Cancellation of Dipole–Dipole Coupling and Chemical Shift Anisotropy Indicates an Avenue to NMR Structures of Very Large Biological Macromolecules in Solution. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 12366–12371. [[CrossRef](#)] [[PubMed](#)]
15. Mulder, F.A.A.; Schipper, D.; Bott, R.; Boelens, R. Altered Flexibility in the Substrate-Binding Site of Related Native and Engineered High-Alkaline Bacillus Subtilisins Edited by P. E. Wright. *J. Mol. Biol.* **1999**, *292*, 111–123. [[CrossRef](#)] [[PubMed](#)]
16. Lee, W.; Tonelli, M.; Markley, J.L. NMRFAM-SPARKY: Enhanced Software for Biomolecular NMR Spectroscopy. *Bioinformatics* **2015**, *31*, 1325–1327. [[CrossRef](#)] [[PubMed](#)]
17. Hamilton, J.A.; Steinrauf, L.K.; Braden, B.C.; Liepnieks, J.; Benson, M.D.; Holmgren, G.; Sandgren, O.; Steen, L. The X-Ray Crystal Structure Refinements of Normal Human Transthyretin and the Amyloidogenic Val30→Met Variant to 1.7-Å Resolution. *J. Biol. Chem.* **1993**, *268*, 2416–2424. [[CrossRef](#)]
18. Jurrus, E.; Engel, D.; Star, K.; Monson, K.; Brandi, J.; Felberg, L.E.; Brookes, D.H.; Wilson, L.; Chen, J.; Liles, K.; et al. Improvements to the APBS Biomolecular Solvation Software Suite. *Protein Sci.* **2018**, *27*, 112–128. [[CrossRef](#)] [[PubMed](#)]
19. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual Molecular Dynamics. *J. Mol. Graph.* **1996**, *14*, 33–38. [[CrossRef](#)]
20. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. *Nucleic Acids Res.* **2000**, *28*, 235–242. [[CrossRef](#)] [[PubMed](#)]
21. Yee, A.W.; Moulin, M.; Breteau, N.; Haertlein, M.; Mitchell, E.P.; Cooper, J.B.; Boeri Erba, E.; Forsyth, V.T. Impact of Deuteration on the Assembly Kinetics of Transthyretin Monitored by Native Mass Spectrometry and Implications for Amyloidoses. *Angew. Chem. Int. Ed.* **2016**, *55*, 9292–9296. [[CrossRef](#)]
22. Williams, C.J.; Headd, J.J.; Moriarty, N.W.; Prisant, M.G.; Videau, L.L.; Deis, L.N.; Verma, V.; Keedy, D.A.; Hintze, B.J.; Chen, V.B.; et al. MolProbity: More and Better Reference Data for Improved All-Atom Structure Validation. *Protein Sci.* **2018**, *27*, 293–315. [[CrossRef](#)]
23. Rodrigues, J.P.G.L.M.; Teixeira, J.M.C.; Trellet, M.; Bonvin, A.M.J.J. Pdb-Tools: A Swiss Army Knife for Molecular Structures. *F1000Research* **2018**, *7*, 1961. [[CrossRef](#)]
24. Dolinsky, T.J.; Nielsen, J.E.; McCammon, J.A.; Baker, N.A. PDB2PQR: An Automated Pipeline for the Setup of Poisson-Boltzmann Electrostatics Calculations. *Nucleic Acids Res.* **2004**, *32*, W665–W667. [[CrossRef](#)] [[PubMed](#)]
25. Phillips, J.C.; Hardy, D.J.; Maia, J.D.C.; Stone, J.E.; Ribeiro, J.V.; Bernardi, R.C.; Buch, R.; Fiorin, G.; Hénin, J.; Jiang, W.; et al. Scalable Molecular Dynamics on CPU and GPU Architectures with NAMD. *J. Chem. Phys.* **2020**, *153*, 044130. [[CrossRef](#)]

26. MacKerell, A.D.; Bashford, D.; Bellott, M.; Dunbrack, R.L.; Evanseck, J.D.; Field, M.J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; et al. All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins. *J. Phys. Chem. B* **1998**, *102*, 3586–3616. [[CrossRef](#)]
27. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of Simple Potential Functions for Simulating Liquid Water. *J. Chem. Phys.* **1983**, *79*, 926–935. [[CrossRef](#)]
28. Project, E.; Nachliel, E.; Gutman, M. The Dynamics of Ca²⁺ Ions within the Solvation Shell of Calbindin D9k. *PLoS ONE* **2011**, *6*, e14718. [[CrossRef](#)]
29. Protein NMR Spectroscopy—2nd Edition. Available online: <https://www.elsevier.com/books/protein-nmr-spectroscopy/cavanagh/978-0-12-164491-8> (accessed on 24 February 2022).
30. Grzesiek, S.; Anglister, J.; Ren, H.; Bax, A. Carbon-13 Line Narrowing by Deuterium Decoupling in Deuterium/Carbon-13/Nitrogen-15 Enriched Proteins. Application to Triple Resonance 4D J Connectivity of Sequential Amides. *J. Am. Chem. Soc.* **1993**, *115*, 4369–4370. [[CrossRef](#)]
31. Corazza, A.; Verona, G.; Waudby, C.A.; Mangione, P.P.; Bingham, R.; Uings, I.; Canetti, D.; Nocerino, P.; Taylor, G.W.; Pepys, M.B.; et al. Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes. *J. Med. Chem.* **2019**, *62*, 8274–8283. [[CrossRef](#)]
32. Williamson, M.P. Using Chemical Shift Perturbation to Characterise Ligand Binding. *Prog. Nucl. Magn. Reson. Spectrosc.* **2013**, *73*, 1–16. [[CrossRef](#)] [[PubMed](#)]
33. Kukic, P.; O’Meara, F.; Hewage, C.; Erik Nielsen, J. Coupled Effect of Salt and PH on Proteins Probed with NMR Spectroscopy. *Chem. Phys. Lett.* **2013**, *579*, 114–121. [[CrossRef](#)]
34. Castro-Rodrigues, A.F.; Gales, L.; Saraiva, M.J.; Damas, A.M. Structural Insights into a Zinc-Dependent Pathway Leading to Leu55Pro Transthyretin Amyloid Fibrils. *Acta Crystallogr. Sect. D* **2011**, *67*, 1035–1044. [[CrossRef](#)]
35. Wilkinson-White, L.E.; Easterbrook-Smith, S.B. Characterization of the Binding of Cu(II) and Zn(II) to Transthyretin: Effects on Amyloid Formation. *Biochemistry* **2007**, *46*, 9123–9132. [[CrossRef](#)]
36. Palmieri, L.D.C.; Lima, L.M.T.; Freire, J.B.; Bleicher, L.; Polikarpov, I.; Almeida, F.C.; Foguel, D. Novel Zn²⁺-Binding Sites in Human Transthyretin: Implications for Amyloidogenesis and Retinol-Binding Protein Recognition. *J. Biol. Chem.* **2010**, *285*, 31731–31741. [[CrossRef](#)] [[PubMed](#)]
37. Ciccone, L.; Fruchart-Gaillard, C.; Mourier, G.; Savko, M.; Nencetti, S.; Orlandini, E.; Servent, D.; Stura, E.A.; Shepard, W. Copper Mediated Amyloid- β Binding to Transthyretin. *Sci. Rep.* **2018**, *8*, 13744. [[CrossRef](#)] [[PubMed](#)]
38. Ghadami, S.A.; Chia, S.; Ruggeri, F.S.; Meisl, G.; Bemporad, F.; Habchi, J.; Cascella, R.; Dobson, C.M.; Vendruscolo, M.; Knowles, T.P.J.; et al. Transthyretin Inhibits Primary and Secondary Nucleations of Amyloid- β Peptide Aggregation and Reduces the Toxicity of Its Oligomers. *Biomacromolecules* **2020**, *21*, 1112–1125. [[CrossRef](#)]
39. Zhang, Y.; Cremer, P.S. Interactions between Macromolecules and Ions: The Hofmeister Series. *Curr. Opin. Chem. Biol.* **2006**, *10*, 658–663. [[CrossRef](#)]
40. Nijst, P.; Verbrugge, F.H.; Grieten, L.; Dupont, M.; Steels, P.; Tang, W.H.W.; Mullens, W. The Pathophysiological Role of Interstitial Sodium in Heart Failure. *J. Am. Coll. Cardiol.* **2015**, *65*, 378–388. [[CrossRef](#)]
41. Khiabani, N.P.; Bahramian, A.; Ejtehadi, M.R.; Chen, P.; Pourafshary, P.; Goddard, W.A. Calcium Chloride Adsorption at Liquid-Liquid Interfaces: A Molecular Dynamics Simulation Study. *Colloids Surf. A Physicochem. Eng. Asp.* **2017**, *527*, 70–80. [[CrossRef](#)]
42. Thelander, U.; Westermark, G.T.; Antoni, G.; Estrada, S.; Zancanaro, A.; Ihse, E.; Westermark, P. Cardiac Microcalcifications in Transthyretin (ATTR) Amyloidosis. *Int. J. Cardiol.* **2022**, *352*, 84–91. [[CrossRef](#)]
43. Roijers, R.B.; Debernardi, N.; Cleutjens, J.P.M.; Schurgers, L.J.; Mutsaers, P.H.A.; van der Vusse, G.J. Microcalcifications in Early Intimal Lesions of Atherosclerotic Human Coronary Arteries. *Am. J. Pathol.* **2011**, *178*, 2879–2887. [[CrossRef](#)] [[PubMed](#)]
44. Stats, M.A.; Stone, J.R. Varying Levels of Small Microcalcifications and Macrophages in ATTR and AL Cardiac Amyloidosis: Implications for Utilizing Nuclear Medicine Studies to Subtype Amyloidosis. *Cardiovasc. Pathol.* **2016**, *25*, 413–417. [[CrossRef](#)] [[PubMed](#)]